Oncology Experts Pinpoint the Key Drivers and Barriers of Biosimilar Adoption

Posted by ZS Editors on Aug 30, 2017 8:00:00 AM

Biosimilars are beginning to permeate the U.S. oncology market, but the floodgates aren’t exactly open. Despite their promise to expand treatment options and rein in cancer costs, biosimilars continue to face prescriber inexperience and other challenges that affect adoption levels. To execute an effective go-to-market strategy in the evolving cancer landscape, biosimilar manufacturers must contend with increasing competition, overcome patent disputes, and develop education programs for biosimilar-naïve stakeholders. Meanwhile, manufacturers of originator products will need to develop effective defense strategies in anticipation of biosimilar competition


>
Read More

Oncology Biosimilars Outlook: How Key Stakeholders Can Plan for Change

Posted by ZS Editors on Jul 24, 2017 1:04:28 PM

With the oncology biosimilars market poised for expansion, ZS launched an effort to survey the landscape. Our 2017 Biosimilar Adoption Study polled 252 respondents—including 200 oncologists, 25 payers and 27 pharmacy directors—and the results provide a perspective on market perceptions and other factors that could drive or restrict oncology biosimilars’ adoption. 


>
Read More

The Elusive Promise of Savings With Biosimilars

Posted by David Weil on Sep 14, 2016 12:00:00 PM


The cost of cancer care in the United States—and its seemingly inexorable rate of growth—has been widely discussed and lamented. The cost of biologic therapies is frequently cited as a driver of this growth, and one that could be addressed with the introduction of less expensive therapeutic options. 


>
Read More

Biosimilars: Facing the Hurdles and Opportunities of Therapeutic Oncology

Posted by Tucker Herbert on May 13, 2016 2:49:06 PM

Despite looming patent expirations, exact-copy “generics” are out of reach for breakthrough oncology drugs such as Rituxan, Herceptin, Avastin and Erbitux given the molecular complexity of biologic medicines. The closest achievable replications are called “biosimilars” because they have demonstrated bioequivalence and non-inferiority. While a few biosimilars have been on the market in Europe for a decade, significant skepticism remains, especially in the space of oncology therapeutics, which represents a $25 billion opportunity in annual revenue.


>
Read More